Harrow, Inc.

Harrow is a leading provider of ophthalmic disease management solutions in North America. The company was founded to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For over a decade, Harrow has partnered with U.S. eyecare professionals to develop a comprehensive portfolio of high-quality products used to manage ophthalmic conditions affecting both the front and back of the eye. These conditions include dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma, and a range of other ocular surface conditions and retina diseases. Harrow has expanded its portfolio of U.S. Food and Drug Administration (FDA)-approved ophthalmic products through acquisitions, licensing transactions, and internal investment, primarily focusing on the U.S. and Canadian markets. The company owns U.S. commercial rights to and markets the following products: IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3%, a low-viscosity gel for ocular surface anesthesia; VEVYE® (cyclosporine ophthalmic solution) 0.1%, a water-free solution for the signs and symptoms of dry eye disease; TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/ml, a steroid injection for certain ophthalmic diseases and vitrectomy visualization; and BYOOVIZ® (ranibizumab-nuna) 0.05mL injection, the first FDA-approved LUCENTIS biosimilar for Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), and Myopic Choroidal Neovascularization (mCNV).